MTNB net incomeQ2 2026-$1.33M
MTNB net income was -$1.33M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$5.25M a year earlier. For the full fiscal 2025 it was -$10.35M, compared with -$24.25M in fiscal 2024.
Matinas Biopharma Holdings Inc. (MTNB) financials
For the twelve months ended Jun 30, 2026, Matinas Biopharma Holdings Inc. reported -$6.69M of net income.
- Net income, TTM
- -$6.69M
- EPS, diluted, TTM
- -$1.15
- Cash
- $761.0K
- Market cap
- $1.2M
FY2016FY2023
FY2016FY2025
FY2016FY2023
MTNB revenue and earnings growth
MTNB EPSQ2 2026-$0.21
MTNB diluted EPS was -$0.21 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.03 a year earlier. For the full fiscal 2025 it was -$2.00, compared with -$4.98 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $1.10M | $3.19M | $33.0K | $158.3K | $89.8K | $119.8K | $149.7K | $0 |
| Research and development | $85.0K | $11.43M | $14.49M | $16.68M | $14.58M | $14.36M | $11.23M | $6.79M | $9.01M | $3.95M |
| Selling, general and admin | $6.88M | $8.73M | $10.37M | $11.10M | $10.19M | $10.01M | $7.78M | $7.98M | $7.64M | $4.31M |
| Operating income | -$6.96M | -$24.59M | -$23.77M | -$24.59M | -$24.73M | -$24.21M | -$18.92M | -$14.65M | -$16.50M | -$8.26M |
| Pre-tax income | -$10.35M | -$24.33M | -$22.94M | - | - | - | - | - | - | - |
| Income tax | - | -$80.0K | - | - | - | - | - | $506.9K | $400.0K | - |
| Net income | -$10.35M | -$24.25M | -$22.94M | -$21.00M | -$23.28M | -$22.45M | -$17.37M | -$14.08M | -$15.49M | -$7.60M |
| EPS, basic | -$2.00 | -$4.98 | -$5.28 | -$5.00 | -$5.50 | -$6.00 | -$6.50 | -$7.50 | -$18.00 | -$10.50 |
| EPS, diluted | -$2.00 | -$4.98 | -$5.28 | -$5.00 | -$5.50 | -$6.00 | -$6.50 | -$7.50 | -$18.00 | -$10.50 |
| Diluted shares | 5.5M | 4.9M | 4.3M | 4.3M | 4.2M | 3.9M | 2.9M | 2.0M | 1.8M | 1.2M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.00M | $7.28M | $4.79M | $6.83M | $21.03M | $12.43M | $22.17M | $13.01M | $7.31M | $4.11M |
| Short-term investments | - | - | $8.97M | $21.93M | $28.59M | $46.25M | $5.60M | - | - | - |
| Current assets | $4.08M | $8.03M | $15.54M | $34.53M | $50.99M | $61.55M | $29.92M | $13.09M | $7.96M | $4.57M |
| Goodwill | - | - | $1.34M | $1.34M | $1.34M | $1.34M | $1.34M | $1.34M | $1.34M | $1.34M |
| Total assets | $7.21M | $12.64M | $25.10M | $44.82M | $61.33M | $70.97M | $40.24M | $19.94M | $14.42M | $9.82M |
| Current liabilities | $1.46M | $2.67M | $2.62M | $4.29M | $4.35M | $3.57M | $3.10M | $2.84M | $1.77M | $1.44M |
| Total liabilities | $2.38M | $5.05M | $5.86M | $8.18M | $8.83M | $7.24M | $7.19M | $3.80M | $3.74M | $2.67M |
| Shareholders' equity | $4.83M | $7.59M | $19.25M | $36.64M | $52.49M | $63.73M | $33.05M | $16.14M | $10.68M | $7.15M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.01M | -$15.88M | -$15.28M | -$19.16M | -$15.22M | -$17.37M | -$14.09M | -$10.32M | -$11.46M | -$6.12M |
| Capital expenditures | - | - | $218.0K | $892.0K | $260.0K | $5.7K | $405.6K | $535.9K | $942.2K | $0 |
| Free cash flow | - | - | -$15.50M | -$20.05M | -$15.48M | -$17.37M | -$14.50M | -$10.86M | -$12.40M | -$6.12M |
| Investing cash flow | $335.0K | $9.21M | $13.24M | $4.88M | $16.77M | -$40.67M | -$6.01M | -$535.9K | -$942.2K | $0 |
| Financing cash flow | $3.39M | $9.17M | -$7.0K | $79.0K | $6.96M | $48.05M | $29.85M | $15.87M | $15.60M | $7.00M |
| Stock-based compensation | $1.02M | $3.19M | $4.95M | $5.23M | $4.29M | $4.56M | $2.99M | $3.83M | $3.60M | $1.52M |
| Depreciation and amortization | $32.0K | $365.0K | $385.0K | $337.0K | $244.0K | $231.1K | $206.0K | $218.3K | $100.6K | $52.6K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | -65.6% | 9560.6% | -79.2% | 76.3% | -25.0% | -20.0% | - | -100.0% |
| Operating margin | - | - | -2168.4% | -771.3% | -74954.5% | -15288.4% | -21067.4% | -12230.9% | -11024.6% | - |
| Net margin | - | - | -2093.2% | -658.6% | -70554.5% | -14177.0% | -19343.4% | -11760.4% | -10345.9% | - |
| Free cash flow margin | - | - | -1413.9% | -628.9% | -46918.2% | -10972.8% | -16142.2% | -9066.5% | -8285.2% | - |
| Return on equity | -214.2% | -319.5% | -119.2% | -57.3% | -44.4% | -35.2% | -52.6% | -87.2% | -145.0% | -106.3% |
| Return on assets | -143.5% | -191.8% | -91.4% | -46.8% | -38.0% | -31.6% | -43.2% | -70.6% | -107.4% | -77.4% |
| Current ratio | 2.79 | 3.01 | 5.93 | 8.06 | 11.73 | 17.25 | 9.66 | 4.61 | 4.50 | 3.16 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $0 | $0 |
| Research and development | - | - | $0 | $0 | $0 | $85.0K | $2.38M | $2.24M | $3.37M | $3.45M | $3.67M | $3.29M |
| Selling, general and admin | $1.55M | $1.94M | $1.60M | $1.58M | $1.84M | $1.86M | $1.66M | $2.14M | $2.47M | $2.46M | $2.22M | $2.84M |
| Operating income | -$1.55M | -$1.94M | -$1.60M | -$1.58M | -$1.84M | -$1.95M | -$8.47M | -$4.38M | -$5.84M | -$5.90M | -$5.89M | -$6.13M |
| Net income | -$1.33M | -$1.92M | -$1.91M | -$1.53M | -$5.25M | -$1.66M | -$8.43M | -$4.28M | -$5.72M | -$5.82M | -$5.31M | -$6.05M |
| EPS, basic | -$0.21 | -$0.30 | -$0.24 | -$0.40 | -$1.03 | -$0.33 | -$1.64 | -$0.85 | -$1.15 | -$1.34 | -$0.89 | -$1.39 |
| EPS, diluted | -$0.21 | -$0.30 | -$0.24 | -$0.40 | -$1.03 | -$0.33 | -$1.64 | -$0.85 | -$1.15 | -$1.34 | -$0.89 | -$1.39 |
| Diluted shares | 6.4M | 6.4M | - | 5.4M | 5.1M | 5.1M | - | 5.0M | 5.0M | 4.3M | - | 4.3M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $761.0K | $2.40M | $4.00M | $5.43M | $6.53M | $6.92M | $7.28M | $10.29M | $4.22M | $1.07M | $4.79M | $6.41M |
| Short-term investments | - | - | - | - | - | - | - | $500.0K | $10.10M | $7.04M | $8.97M | $11.81M |
| Current assets | $1.14M | $2.81M | $4.08M | $5.65M | $7.27M | $7.55M | $8.03M | $11.74M | $15.29M | $10.29M | $15.54M | $19.99M |
| Goodwill | - | - | - | - | - | - | - | $1.34M | $1.34M | $1.34M | $1.34M | $1.34M |
| Total assets | $3.41M | $5.87M | $7.21M | $9.70M | $11.42M | $12.04M | $12.64M | $20.58M | $24.36M | $19.61M | $25.10M | $29.79M |
| Current liabilities | $1.35M | $2.13M | $1.46M | $1.50M | $1.78M | $2.25M | $2.67M | $2.12M | $2.39M | $2.00M | $2.62M | $3.23M |
| Total liabilities | $1.61M | $2.85M | $2.38M | $3.23M | $3.75M | $5.76M | $5.05M | $4.80M | $5.26M | $5.05M | $5.86M | $6.64M |
| Shareholders' equity | $1.80M | $3.02M | $4.83M | $6.46M | $7.67M | $6.27M | $7.59M | $15.78M | $19.10M | $14.56M | $19.25M | $23.15M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.84M | -$1.60M | -$1.51M | -$1.47M | -$2.02M | -$2.01M | -$3.51M | -$3.50M | -$3.11M | -$5.77M | -$4.58M | -$4.42M |
| Capital expenditures | - | - | - | - | - | - | - | - | - | - | $0 | $16.0K |
| Free cash flow | - | - | - | - | - | - | - | - | - | - | -$4.58M | -$4.43M |
| Investing cash flow | - | - | $15.0K | - | - | - | $500.0K | $9.65M | -$2.94M | $2.00M | $2.96M | $1.08M |
| Financing cash flow | - | - | $58.0K | $64.0K | $1.62M | $1.65M | -$1.0K | -$67.0K | $9.19M | $53.0K | -$1.0K | -$1.0K |
| Stock-based compensation | $104.0K | $113.0K | $217.0K | $253.0K | $238.0K | $315.0K | $244.0K | $965.0K | $991.0K | $995.0K | $1.27M | $1.20M |
| Depreciation and amortization | $0 | $0 | $3.0K | $2.0K | $12.0K | $18.0K | $90.0K | $90.0K | $90.0K | $94.0K | $97.0K | $98.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | - | - | - | - | -100.0% | -100.0% |
| Current ratio | 0.85 | 1.32 | 2.79 | 3.78 | 4.07 | 3.35 | 3.01 | 5.53 | 6.39 | 5.15 | 5.93 | 6.19 |
Source: XBRL data Matinas Biopharma Holdings Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-50, first reported Nov 13, 2024.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
MTNB peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| MTNB | - | - | -$6.69M | - | $1.2M |
| STRO | $45.70M | -56.3% | -$180.64M | -395.2% | $175.9M |
| CUE | $37.65M | +354.4% | -$164.11M | -435.8% | $146.3M |
| GTBP | - | - | -$4.76M | - | $8.9M |
MTNB FAQ
5 questionsIs MTNB profitable?
No. Matinas Biopharma Holdings Inc. reported a net loss of $6.69M for the twelve months ended Jun 30, 2026.How much cash and debt does MTNB have?
Matinas Biopharma Holdings Inc. reported $761.0K in cash and cash equivalents on its most recent balance sheet in SEC filings.What is MTNB earnings per share?
Diluted earnings per share were -$1.15 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did MTNB last report financial results?
The latest statements here come from Matinas Biopharma Holdings Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.Where does this MTNB financial data come from?
Quantisnow builds these statements from the structured XBRL data Matinas Biopharma Holdings Inc. files with the SEC. It is provided for information only and is not investment advice.